BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 18503889)

  • 1. Vascular endothelial growth factor in chronic rat allograft nephropathy.
    Malmström NK; Kallio EA; Rintala JM; Nykänen AI; Räisänen-Sokolowski AK; Paavonen T; Lemström KB; Koskinen PK
    Transpl Immunol; 2008 May; 19(2):136-44. PubMed ID: 18503889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor (VEGF) ligand and receptor induction in rat renal allograft rejection.
    Rintala SE; Savikko J; Rintala JM; von Willebrand E
    Transplant Proc; 2006 Dec; 38(10):3236-8. PubMed ID: 17175233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition.
    Zips D; Eicheler W; Geyer P; Hessel F; Dörfler A; Thames HD; Haberey M; Baumann M
    Cancer Res; 2005 Jun; 65(12):5374-9. PubMed ID: 15958586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting lymphatic vessel activation and CCL21 production by vascular endothelial growth factor receptor-3 inhibition has novel immunomodulatory and antiarteriosclerotic effects in cardiac allografts.
    Nykänen AI; Sandelin H; Krebs R; Keränen MA; Tuuminen R; Kärpänen T; Wu Y; Pytowski B; Koskinen PK; Ylä-Herttuala S; Alitalo K; Lemström KB
    Circulation; 2010 Mar; 121(12):1413-22. PubMed ID: 20231530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity.
    Yamamoto A; Watanabe H; Sueki H; Nakanishi T; Yasuhara H; Iijima M
    J Dermatol; 2007 Jul; 34(7):419-29. PubMed ID: 17584317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of fractalkine, CX3CR1, and vascular endothelial growth factor in human chronic renal allograft rejection.
    Cao G; Lu Y; Gao R; Xin Y; Teng D; Wang J; Li Y
    Transplant Proc; 2006 Sep; 38(7):1998-2000. PubMed ID: 16979977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells.
    Lacal PM; Ruffini F; Pagani E; D'Atri S
    Int J Oncol; 2005 Dec; 27(6):1625-32. PubMed ID: 16273219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis.
    Scaldaferri F; Vetrano S; Sans M; Arena V; Straface G; Stigliano E; Repici A; Sturm A; Malesci A; Panes J; Yla-Herttuala S; Fiocchi C; Danese S
    Gastroenterology; 2009 Feb; 136(2):585-95.e5. PubMed ID: 19013462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
    Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VEGFR-1 and -2 regulate inflammation, myocardial angiogenesis, and arteriosclerosis in chronically rejecting cardiac allografts.
    Raisky O; Nykänen AI; Krebs R; Hollmén M; Keränen MA; Tikkanen JM; Sihvola R; Alhonen L; Salven P; Wu Y; Hicklin DJ; Alitalo K; Koskinen PK; Lemström KB
    Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):819-25. PubMed ID: 17290032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction.
    Ko HT; Yin JL; Wyburn K; Wu H; Eris JM; Hambly BD; Chadban SJ
    Nephrol Dial Transplant; 2013 Feb; 28(2):327-36. PubMed ID: 23229928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1.
    Hazarika S; Dokun AO; Li Y; Popel AS; Kontos CD; Annex BH
    Circ Res; 2007 Oct; 101(9):948-56. PubMed ID: 17823371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FK778 ameliorates post-transplant expression of fibrogenic growth factors and development of chronic rejection changes in rat kidney allografts.
    Rintala JM; Savikko J; Rintala SE; von Willebrand E
    Nephrol Dial Transplant; 2008 Nov; 23(11):3446-55. PubMed ID: 18558624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive immunohistological analysis of the endothelin system in human kidney grafts.
    Frank K; Zeier M; Gross ML; Waldherr R; Ritz E; Amann K
    Nephrol Dial Transplant; 2006 May; 21(5):1365-72. PubMed ID: 16449275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential regulation of vascular endothelial growth factor receptors (VEGFR) revealed by RNA interference: interactions of VEGFR-1 and VEGFR-2 in endothelial cell signaling.
    Kou R; SenBanerjee S; Jain MK; Michel T
    Biochemistry; 2005 Nov; 44(45):15064-73. PubMed ID: 16274253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability.
    Patel N; Sun L; Moshinsky D; Chen H; Leahy KM; Le P; Moss KG; Wang X; Rice A; Tam D; Laird AD; Yu X; Zhang Q; Tang C; McMahon G; Howlett A
    J Pharmacol Exp Ther; 2003 Sep; 306(3):838-45. PubMed ID: 12766257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor plays a major role in development of experimental obliterative bronchiolitis.
    Krebs R; Hollmén ME; Tikkanen JM; Wu Y; Hicklin DJ; Koskinen PK; Lemström KB
    Transplant Proc; 2006 Dec; 38(10):3266-7. PubMed ID: 17175244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1 follicular thyroid carcinoma cells.
    Balthasar S; Bergelin N; Löf C; Vainio M; Andersson S; Törnquist K
    Endocr Relat Cancer; 2008 Jun; 15(2):521-34. PubMed ID: 18509004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice.
    Ou XM; Li WC; Liu DS; Li YP; Wen FQ; Feng YL; Zhang SF; Huang XY; Wang T; Wang K; Wang X; Chen L
    Int Immunopharmacol; 2009 Jan; 9(1):70-9. PubMed ID: 18976720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor receptor-1 regulates postnatal angiogenesis through inhibition of the excessive activation of Akt.
    Nishi J; Minamino T; Miyauchi H; Nojima A; Tateno K; Okada S; Orimo M; Moriya J; Fong GH; Sunagawa K; Shibuya M; Komuro I
    Circ Res; 2008 Aug; 103(3):261-8. PubMed ID: 18583712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.